
For the first time a vaccine will be available to help seniors fight RSV — respiratory syncytial virus — for the fall respiratory season, though potentially in a limited amount for the start.
The vaccine was developed by GSK. Dessi Loukov, Scientific Lead – Vaccines, GSK, joins Patricia Boal to talk through RSV and its health risks and how the vaccine can make a difference in confronting those.













